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CASE REPORT
HEART CARE TEAM/MULTIDISCIPLINARY TEAM LIVE

Fulminant Giant Cell Myocarditis
Requiring Bridge With Mechanical
Circulatory Support to
Heart Transplantation
Yevgeniy Brailovsky, DO, MSC,a Amirali Masoumi, MD,b Rachel Bijou, MD,b Estefania Oliveros, MD, MSC,c
Gabriel Sayer, MD,b Koji Takeda, MD, PHD,d Nir Uriel, MD, MSCb

ABSTRACT
Giant cell myocarditis is a rare cause of cardiogenic shock requiring a high index of suspicion, rapid immunosuppressive
therapy, and mechanical circulatory support. We present the case of a patient with giant cell myocarditis who underwent
a successful bridge with four different types of mechanical circulatory support devices to heart transplantation. (Level of
Difﬁculty: Advanced.) (J Am Coll Cardiol Case Rep 2022;4:265–270) © 2022 The Authors. Published by Elsevier on
behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).

G

iant cell myocarditis (GCM) is a rare cause of

sentation, who had a delay in pathologic diagnosis

cardiogenic shock requiring a high index of

amid the COVID-19 pandemic, but eventually under-

suspicion, rapid immunosuppressive ther-

went successful bridge with four different types of

apy, and mechanical circulatory support. We present

mechanical circulatory support devices to orthotopic

the case of a patient with GCM based on clinical pre-

heart transplantation (OHT).

LEARNING OBJECTIVES
 To recognize giant cell myocarditis as a cause
of cardiogenic shock resulting from biventricular heart failure and ventricular
arrhythmias.
 To engage the multidisciplinary team in the
decision pathways for escalation of mechanical circulatory support to preserve endorgan function and improve survival.

CASE PRESENTATION
Our patient is a 69-year-old woman with nonischemic
dilated cardiomyopathy and a left ventricular ejection
fraction (LVEF) of 35%, who recovered her LVEF with
guideline-directed

medical

therapy

and

cardiac

resynchronization therapy. She now presented with
1 week of fever, chills, diarrhea, and worsening dyspnea. There were signs and symptoms of shock and
end-organ hypoperfusion.
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ABBREVIATIONS

QUESTION 1: WHAT IS THE

with GCM; however, the direct link to pathogenesis is

AND ACRONYMS

DIFFERENTIAL DIAGNOSIS AND WHAT

limited. 2 Our patient had evidence of Coxsackie B

IS THE DIAGNOSTIC APPROACH?

virus on presentation, but it is not clear whether this

ECMO = extracorporeal

was pathologically linked in this case.

membrane oxygenation

GCM = giant cell myocarditis
LVAD = left ventricular assist
device

LVEF = left ventricular ejection

Differential diagnoses included acute coro-

Immunosuppression is the cornerstone of medical

nary syndrome, fulminant myocarditis, sep-

management of GCM. However, ideal immunosup-

tic

acute

pression is not known because of the scarcity of high-

pulmonary embolism, and acute aortic syn-

quality data.2 Management usually involves two- or

shock,

COVID-19

infection,

fraction

drome. The initial workup revealed a nega-

three-drug regimens with corticosteroids, a calci-

OHT = orthotopic heart

tive result of SARS CoV-2 polymerase chain

neurin inhibitor (cyclosporine or tacrolimus), azathi-

transplantation

reaction testing and an elevated Coxsackie B

oprine, or mycophenolate mofetil. Alternatively,

PA = pulmonary artery

virus titer to 1:320. The transthoracic echo-

more aggressive management with an antithymocyte

RA = right atrium

cardiogram demonstrated LVEF of 20%, se-

globulin or alemtuzumab have also been used.2 The

RV = right ventricle

vere right ventricular (RV) dysfunction, and

impact of immunotherapy before transplant is un-

severe mitral regurgitation. A right heart

known, and a signiﬁcant proportion of patients

catheterization revealed a right atrial (RA) pressure of

experience

6 mm Hg, RV pressure of 32/9 mm Hg, pulmonary

management.3,4

progression

despite

medical

artery (PA) pressure of 30/20/25 mm Hg, pulmonary
capillary wedge pressure of 22 mm Hg with V waves of

QUESTION 4: WHAT ARE THE OPTIONS FOR

30 mm Hg, left ventricular end diastolic pressure of

TEMPORARY MECHANICAL CIRCULATORY

32 mm Hg, cardiac output of 3.3 L/min, and cardiac

SUPPORT FOR CARDIOGENIC SHOCK AND
WHICH SUPPORT IS MOST APPROPRIATE FOR

index

of

1.95

L/min/m2 .

An

electrocardiogram

revealed markedly low voltage and ventricular paced

OUR PATIENT?

rhythm (Figure 1). A coronary angiogram revealed
nonobstructive coronary artery disease.

QUESTION 2: WHEN SHOULD GCM BE
SUSPECTED AND HOW IS THE DIAGNOSIS
ESTABLISHED?
Acute cardiogenic shock and incessant ventricular
arrhythmia raise the clinical suspicion for GCM.
However, the presentation can vary in severity, and
maintaining a high clinical suspicion is imperative to
establishing a correct diagnosis. An early endomyocardial biopsy can establish the diagnosis and lead to
the implementation of therapy. 1,2
Endomyocardial biopsy is limited by sampling error and lacks the sensitivity to deﬁnitively rule out
GCM, as occurred in our patient. 3 Considering a
worsening cardiovascular status and with positive
viral titers, there was a high suspicion for myocarditis. Therefore, our patient underwent a cardiac biopsy on hospital day 12 and was treated with empiric
high-dose steroids with 1 g methylprednisolone. The
endomyocardial biopsy results were nondiagnostic.

QUESTION 3: WHAT IS THE
PATHOPHYSIOLOGY OF GCM AND WHAT ARE
THE OPTIONS FOR MEDICAL THERAPY?

The choice of support depends on the severity of
cardiogenic shock, the underlying cause of the shock,
the chambers involved, and the amount of support
required. It is imperative determine the chambers
involved: either left ventricle or RV or both. There are
four basic conﬁgurations for support: 1) drainage from
the right atrium (RA)/inferior vena cava/superior
vena cava and return to the systemic arterial system;
2) drainage from the LA and return to the systemic
arterial system; 3) drainage from the LV and return to
the aorta; and 4) drainage from the inferior vena
cava/superior vena cava/RA and return into the PA.
The device chosen after a multidisciplinary discussion will provide different amounts of support from
0.5 to 10 L/min. The LV support includes intra-aortic
balloon pump, LV-aortic microaxial pump, or extracorporeal membrane oxygenation (ECMO). RV support

may

be

provided

percutaneously

with

a

microaxial RA-PA pump or an extracorporeal RA-PA
pump. Biventricular support may be established
with ECMO or a surgical extracorporeal pump with
central

cannulation,

and

by

various

other

combinations.
Although the RV is often involved with myocarditis, the multidisciplinary team decided to proceed
with left-sided support alone because of the normal

The cause of GCM is unclear, but it is characterized by

RA pressure at the time of RHC. Inasmuch as recovery

inﬂammatory inﬁltration of the myocardium by T-

in these patients is often prolonged, we opted for an

lymphocytes and macrophages.2 Some autoimmune

axillary LV-aortic microaxial pump, which can main-

disorders and viral myocarditis have been associated

tain support over days to weeks while permitting
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F I G U R E 1 Electrocardiogram

Hospital day 15, marked low voltage, V-paced.

patients to ambulate if possible. The patient’s he-

the

modynamics stabilized brieﬂy, but soon afterward,

refractory arrhythmias that were associated with

she experienced worsening shock with acute kidney

progressive multiorgan system dysfunction. To pro-

and liver injury and incessant ventricular tachy-

vide higher ﬂows while also ensuring complete

cardia/ﬁbrillation requiring multiple shocks. She was

decompression of both sides of the heart, we decided

treated with intravenous lidocaine, amiodarone, and

to escalate her mechanical circulatory support to a

procainamide drips. Because of the critical cardio-

surgical temporary biventricular assist device with an

genic shock with refractory arrhythmias, the support

oxygenator and with drainage cannulas in RA and LV

was escalated to venoarterial-ECMO in addition to an

apex and reinfusion cannula in the ascending aorta

axillary LV-aortic microaxial pump on hospital day 14

(Figure 2).

PA

(Figure

2).

However,

she

experienced

(Figure 2).
With that support, analysis of the patient’s hemodynamics revealed an RA of 11 mm Hg, PA of 22/18/

QUESTION 5: WHAT ARE THE SURGICAL
OPTIONS FOR GCM?

19 mm Hg, pulmonary capillary wedge pressure of
20 mm Hg, and a mixed venous saturation of 78%

Mechanical circulatory support and heart trans-

with 4 L of ECMO ﬂow and 1.4 L of LV-aortic pump

plantation are often the ultimate therapies for severe

ﬂow on the P4 setting. Given the patient’s refractory

GCM. Montero et al. 5 describe the French experience

cardiogenic shock and continued electrical insta-

of using mechanical circulatory support in 13 patients

bility, she was transferred to the hospital day 15 for

with severe GCM, 85% of whom required veno-

consideration of durable mechanical support or OHT.

arterial ECMO support. Four patients died while using

After a preliminary evaluation revealed no major

mechanical circulatory support, and nine underwent

contraindications to heart transplantation, the team

OHT.5 In a recent systematic review, Patel et al 6

opted to continue with the temporary mechanical

described the outcomes in patients with GCM who

circulatory support while the transplantation evalu-

required mechanical circulatory support. The authors

ation was rapidly completed. However, there was

found that similarly to our case, the vast majority of

concern

precipitating

patients (76.7%) required biventricular support, and

thrombus formation in the pulmonary arteries;

58.5% underwent OHT.6 Ma et al 7 recently described a

therefore, a PA outﬂow cannula was added through

similar case of a patient with fulminant GCM,

the right internal jugular vein to maintain ﬂow in

requiring biventricular support. Unlike the patient in

about

low

PA

pulsatility

267

268

Brailovsky et al

JACC: CASE REPORTS, VOL. 4, NO. 5, 2022

Fulminant Giant Cell Myocarditis

MARCH 2, 2022:265–270

F I G U R E 2 Hospital Course

Figure was created with Biorender.com. BiVAD ¼ biventricular assist device; ECMO ¼ extracorporeal membrane oxygenation; LVAD ¼ left ventricular assist device.

our case, their patient was signiﬁcantly older and was

GCM are poor, and these patients are often not

not a candidate for OHT or durable VAD. The patient

responsive to medical management alone. Funda-

was successfully treated with antithymocyte globulin

mental to the successful treatment of our patient with

and pulse-dose intravenous methylprednisolone, and

severe cardiogenic shock was early reassessment after

underwent transition away from mechanical circula-

each intervention and the ability to quickly transition

tory support and was discharged with maintenance

to a higher level of mechanical circulatory support

immunosuppression. 7 Patel et al8 described another

when needed. In particular, we needed to address the

case of a young man with fulminant GCM who

limitation of peripheral venoarterial-ECMO to main-

required temporary biventricular support with an LV-

tain adequate ﬂow in the PA when RV function is

aorta pump and an RA-PA pump. The patient was

extremely poor or refractory arrhythmias are present.

eventually able to undergo transition to a durable left

In these situations, it is sometimes necessary to

ventricular assist device (LVAD) without RV support.8

switch to surgical ventricular assist devices to provide

Fallon et al 9 described a more indolent course in a

adequate decompression of the ventricles while

patient with progressive heart failure treated for

maintaining appropriate levels of systemic ﬂow.

presumed GCM over a 10-year period. Their patient

Our patient underwent expedited evaluation for

was treated with immunosuppression and durable

durable mechanical circulatory support and OHT. On

LVAD as a bridge to a successful OHT.9 These cases

hospital day 18, she was urgently listed for OHT for

highlight the wide range of acuity of presentations in

cardiogenic shock with surgically implanted VAD

patients with GCM and the need for up-front aggres-

support. On hospital day 20, she underwent OHT

sive therapy in most cases.

without complications. Her immediate postoperative

Unfortunately, the available data on GCM are

support included dobutamine 10 m g/kg/min, norepi-

limited to case reports and small case series. The out-

nephrine 2 m g/min, inhaled nitric oxide 20 ppm, but

comes in patients presenting with a severe form of

no mechanical circulatory support. Vasopressors,
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F I G U R E 3 Heart Explanted Pathological Specimen

Massive myocarditis with an inﬁltrate predominantly of lymphocytes, numerous mononuclear cells, scattered eosinophils, and multinucleate
giant cells. Extensive healing ﬁbrosis, which appears to be approximately 2 weeks old.

inotropes, and inhaled nitric oxide were successfully

needed to provide care in a complex clinical scenario

weaned by postoperative day 3, and she was extu-

like that of the patient we describe. The rapid

bated by postoperative day 4. Pathologic examination

escalation of support devices is warranted in fulmi-

of the explanted heart was consistent with GCM

nant cases to preserve end-organ function and

(Figure 3).

improve survival.

CONCLUSIONS
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